CC BY-NC-ND 4.0 · J Lab Physicians 2009; 1(01): 007-010
DOI: 10.4103/0974-2727.44423
Original Article

Detection of Extended Spectrum β-lactamase Production Among Uropathogens

Ritu Aggarwal
Department of Microbiology, Pt. B.D.Sharma Post Graduate Institute of Medical Sciences, Rohtak-124 001, Haryana, India
Uma Chaudhary
Department of Microbiology, Pt. B.D.Sharma Post Graduate Institute of Medical Sciences, Rohtak-124 001, Haryana, India
Rama Sikka
Department of Microbiology, Pt. B.D.Sharma Post Graduate Institute of Medical Sciences, Rohtak-124 001, Haryana, India
› Author Affiliations
Source of Support: Nil


Background: Detection of extended spectrum β -lactamase (ESBL) production among uropathogens is an important marker of endemicity.

Aim: Intervention of this endemic transmission is important for the control of initial outbreak of ESBL producing organisms in a hospital or specialized unit of hospital.

Materials and Methods: During the study period of one and a half months, 1,551 urine samples were processed for significant bacteriuria. Two hundred gram negative bacterial isolates were tested for ESBL production. Antimicrobial sensitivity pattern was ascertained for ESBL producing isolates.

Results: ESBL production was seen in 36% of isolates. All the isolates were multidrug resistant with uniform sensitivity to imipenem.

Conclusion: This study reveals the significant prevalence of ESBL producing organisms in this north Indian tertiary care hospital. Constant revision of antibiotic policies with infection control interventions is suggested.

Publication History

Publication Date:
29 January 2020 (online)

© 2009.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India


  • 1 Paterson DL, Bonomo RA. Extended spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.
  • 2 Nathisuwan S, Burgess DS, Lewis JS 2nd. Extended Spectrum β-lactamases: Epidemiology, Detection and treatment. Pharmacotherapy 2001;21:920-8.
  • 3 Rupp ME, Fey PD. Extended Spectrum β-lactamase (ESBL) - Producing Enterobacteriaceae. Drugs 2003;63;353-65.
  • 4 Duguid JP, Collee JG, Fraser AG. Laboratory strategy in the diagnosis of infective syndromes. In: Collee JG, Duguid JP, Fraser AG, Marmion BP, editors. Mackie and MacCartney: Practical Medical Microbiology. 13th ed. Singapore: Longman Singapore Publishers; 1989. p. 600-49.
  • 5 Bauer AW, Kirby W, Sherris J, Turck M. Antibiotic susceptibility testing by a standard single disc method. Am J Clin Pathol 1996;45:493-6.
  • 6 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility: sixteenth informational supplement. Wayne, PA, USA:CLSI: 2006; M100-S16.
  • 7 Gupta N, Yadav A, Choudhary U, Arora DR. Citrobacter bacteremia in a tertiary care hospital. Scand J Infect Dis 2003;35:765-8.
  • 8 Ananthkrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of extended spectrum beta lactamase producers among surgical wound infections and burn patients in JIPMER. Ind J Med Microbiol 2000;18:160-5.
  • 9 Brigante G, Luzzaro F, Perilli M, Lombardi G, Colμ A, Rossolini GM, et al. Evolution of CTX-M type beta -lactamasees in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents 2005;25:157-62.
  • 10 Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β-lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.
  • 11 Babypadmini S, Appalaraju B. Extended spectrum β lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital.. Indian J Med Microbiol 2004;22:172-4.
  • 12 Subha A, Ananthan S. Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 2002;20:92-5.
  • 13 Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum β lactamases producing Klebsiella pneumoniae in a tertiary care hospital. Indian J Med Microbiol 2004;22:87-91.
  • 14 Revathi G. Detection of extended spectrum β-lactamases using E-test ESBL strip. Indian J Med Microbiol 1997;15;69-71.
  • 15 Uma A, Mehta A, Ayyagari A, Kapil A, Shahnvi A, Rodrigues C et al. Prevalence of β-lactamase producing strains among clinical isolates obtained from hospital in patients across India and comparison of anti-bacterial susceptibility using disc diffusion method. EGAST 2000. Hospital Today 2004;9:70-80.
  • 16 Peρa C, Pujol M, Ardanuy C, Ricart A, Pallares R, Liρares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended spectrum β-lactamases. Antimicrob Agents Chemother 1998;42:53-8.
  • 17 Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001:32:S94-103.
  • 18 Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum β-lactamase mediated resistance to third generation cephalosporins in Nagpur, Central India. Indian J Med Res 1997;105:153-61.
  • 19 Paterson DL, Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended spectrum β-lactamase (ESBL). Clin Micriobiol Infect 2000;6:460-3.
  • 20 Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum β-lactamase. J Antimicrob Chemother 1996;37:203-4.